Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers-Reference-Cited by-同舟云学术

Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers

Published:2022-05-25 Issue:1 Volume:29 Page:1620-1630
ISSN:1071-7544
Container-title:Drug Delivery
language:en
Short-container-title:Drug Delivery

Author:

Liang Ruijia¹,Wu Cheng²,Liu Shiming²,Zhao Wenyan³^ORCID

Affiliation:

1. Department of Neurosurgery, Hangzhou Medical College Affiliated Lin’an People’s Hospital, The First People’s Hospital of Hangzhou Lin’an District, Hangzhou, China

2. Department of Neurosurgery, Cancer Center, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, China

3. Department of General Practice Medicine, Center for General Practice Medicine, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, China

Funder

Zhejiang Province Public Welfare Technology Application Research Project

Zhejiang Province Health Science and Technology Plan

Medical Science and Technology Project of Zhejiang Province

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/10717544.2022.2075986

Reference121 articles.

1. Smart biomaterials to enhance the efficiency of immunotherapy in glioblastoma: State of the art and future perspectives